19.98
0.14 (0.71%)
| Penutupan Terdahulu | 19.84 |
| Buka | 19.85 |
| Jumlah Dagangan | 922,470 |
| Purata Dagangan (3B) | 3,669,039 |
| Modal Pasaran | 4,769,905,152 |
| Harga / Pendapatan (P/E TTM) | 23.79 |
| Harga / Pendapatan (P/E Ke hadapan) | 28.99 |
| Harga / Jualan (P/S) | 12.74 |
| Harga / Buku (P/B) | 15.26 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2025 |
| Margin Keuntungan | 46.35% |
| Margin Operasi (TTM) | 32.60% |
| EPS Cair (TTM) | 0.830 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 59.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 1,300.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 23.53% |
| Nisbah Semasa (MRQ) | 5.97 |
| Aliran Tunai Operasi (OCF TTM) | 118.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 75.16 M |
| Pulangan Atas Aset (ROA TTM) | 21.24% |
| Pulangan Atas Ekuiti (ROE TTM) | 81.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | ADMA Biologics Inc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.90 |
|
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.59% |
| % Dimiliki oleh Institusi | 88.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Perpetual Ltd | 31 Mar 2025 | 3,551,813 |
| Oberweis Asset Management Inc/ | 31 Mar 2025 | 3,426,260 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 32.00 (Raymond James, 60.16%) | Beli |
| Median | 28.50 (42.64%) | |
| Rendah | 25.00 (Cantor Fitzgerald, 25.13%) | Beli |
| Purata | 28.50 (42.64%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 19.11 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Raymond James | 08 May 2025 | 32.00 (60.16%) | Beli | 21.20 |
| Cantor Fitzgerald | 04 Mar 2025 | 25.00 (25.13%) | Beli | 17.01 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GUIHEEN LAWRENCE P. | - | 20.14 | -9,000 | -181,129 |
| Jumlah Keseluruhan Kuantiti Bersih | -9,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -181,129 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 20.14 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| GUIHEEN LAWRENCE P. | Pengarah | 22 May 2025 | Jual (-) | 1,221 | 20.16 | 24,615 |
| GUIHEEN LAWRENCE P. | Pengarah | 22 May 2025 | Pelaksanaan pilihan | 1,221 | - | - |
| GUIHEEN LAWRENCE P. | Pengarah | 21 May 2025 | Jual (-) | 7,779 | 20.12 | 156,513 |
| GUIHEEN LAWRENCE P. | Pengarah | 21 May 2025 | Pelaksanaan pilihan | 7,779 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 May 2025 | Pengumuman | ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update |
| 30 Apr 2025 | Pengumuman | ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025 |
| 28 Apr 2025 | Pengumuman | ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process |
| 07 Apr 2025 | Pengumuman | ADMA Biologics Statement on Tariffs |
| 03 Mar 2025 | Pengumuman | ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |